Independent Solutions Wealth Management LLC Sells 94 Shares of Becton, Dickinson and Company $BDX

Independent Solutions Wealth Management LLC cut its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 6.6% during the second quarter, Holdings Channel reports. The fund owned 1,320 shares of the medical instruments supplier’s stock after selling 94 shares during the period. Independent Solutions Wealth Management LLC’s holdings in Becton, Dickinson and Company were worth $227,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the business. GQG Partners LLC bought a new position in Becton, Dickinson and Company in the 1st quarter valued at $689,833,000. Vanguard Group Inc. boosted its position in Becton, Dickinson and Company by 4.7% in the 1st quarter. Vanguard Group Inc. now owns 28,002,802 shares of the medical instruments supplier’s stock valued at $6,414,322,000 after buying an additional 1,259,750 shares during the last quarter. Nuveen LLC bought a new position in Becton, Dickinson and Company in the 1st quarter valued at $211,097,000. Kingstone Capital Partners Texas LLC bought a new position in Becton, Dickinson and Company in the 2nd quarter valued at $155,080,000. Finally, Massachusetts Financial Services Co. MA boosted its position in Becton, Dickinson and Company by 10.8% in the 1st quarter. Massachusetts Financial Services Co. MA now owns 6,843,856 shares of the medical instruments supplier’s stock valued at $1,567,654,000 after buying an additional 667,957 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors.

Becton, Dickinson and Company Stock Performance

Shares of Becton, Dickinson and Company stock opened at $192.56 on Wednesday. The company has a market capitalization of $55.19 billion, a PE ratio of 34.63, a PEG ratio of 1.50 and a beta of 0.25. Becton, Dickinson and Company has a 12 month low of $163.33 and a 12 month high of $251.99. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. The stock’s fifty day simple moving average is $189.41 and its 200 day simple moving average is $186.83.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $3.68 EPS for the quarter, topping the consensus estimate of $3.40 by $0.28. The business had revenue of $5.51 billion for the quarter, compared to the consensus estimate of $5.50 billion. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The firm’s revenue was up 10.4% compared to the same quarter last year. During the same quarter last year, the business posted $3.50 EPS. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. On average, research analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th were paid a $1.04 dividend. The ex-dividend date of this dividend was Monday, September 8th. This represents a $4.16 annualized dividend and a dividend yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 74.82%.

Analysts Set New Price Targets

BDX has been the topic of a number of recent research reports. Piper Sandler reiterated a “neutral” rating and issued a $200.00 price objective (up from $185.00) on shares of Becton, Dickinson and Company in a research report on Friday, August 8th. Argus increased their price objective on Becton, Dickinson and Company from $220.00 to $230.00 in a research report on Monday, September 15th. Royal Bank Of Canada started coverage on Becton, Dickinson and Company in a research note on Thursday, September 25th. They issued a “sector perform” rating and a $211.00 price target on the stock. Weiss Ratings reissued a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research note on Saturday, September 27th. Finally, Morgan Stanley increased their price target on Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a research note on Monday, August 11th. Three analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat.com, Becton, Dickinson and Company presently has an average rating of “Hold” and an average target price of $205.40.

Insider Activity

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,185 shares of Becton, Dickinson and Company stock in a transaction dated Friday, July 18th. The stock was sold at an average price of $180.29, for a total value of $213,643.65. Following the sale, the executive vice president owned 4,887 shares of the company’s stock, valued at $881,077.23. This trade represents a 19.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Claire Fraser sold 917 shares of Becton, Dickinson and Company stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the completion of the sale, the director directly owned 22,226 shares in the company, valued at $4,167,375. This represents a 3.96% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 3,023 shares of company stock worth $562,036 in the last three months. Company insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.